Does radiotherapy still have a place in Hodgkin lymphoma?
- Joachim Yahalom
- … show all 1 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Over half a century, radiation therapy (RT) for Hodgkin lymphoma has been transformed from a radical, extensive, high-dose therapy (which alone cured most patients) into an essential component of a comprehensive combined-modality program. RT is now used in a “mini” version that encompasses only the clinically involved sites following chemotherapy and is administered in a markedly reduced dose. This change has considerably reduced the long-term complications that were associated with the now-outdated radical RT approach. The use of RT also allows a shorter and safer course of chemotherapy. The combination of reduced chemotherapy followed by mini-RT has produced disease control and even overall results that are significantly superior to those achieved with chemotherapy alone. This review discusses controversial issues regarding RT, the studies that have addressed them, the new indications for integrating RT, and the safety of minimizing the radiation field and dose.
- Kaplan HS: Clinical evaluation and radiotherapeutic management of Hodgkin’s disease and the malignant lymphomas. N Engl J Med 1968, 278:892–899. CrossRef
- Ng AK, Bernardo MP, Weller E, et al.: Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol 2002, 20:2101–2108. CrossRef
- Longo DL: Hodgkin disease: the sword of Damocles resheathed [comment]. Blood 2004, 104:3418. CrossRef
- Yahalom J: “Don’t throw out the baby with the bathwater”—On optimizing cure and reducing toxicity in Hodgkin lymphoma. J Clin Oncol 2006, 24:544–548. CrossRef
- DeVita VT Jr: Hodgkin’s disease-clinical trials and travails. N Engl J Med 2003, 348:2375–2376. CrossRef
- Noordijk EM, Thomas J, Fermé C, et al.: First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL) [abstract 6505]. J Clin Oncol 2005, 23(June 1 Suppl):6505.
- Laskar S, Gupta T, Vimal S, et al.: Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need? J Clin Oncol 2004, 22:62–68. CrossRef
- Straus DJ, Portlock CS, Qin J, et al.: Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004, 104:3483–3489. CrossRef
- Meyer RM, Gospodarowicz MK, Connors JM, et al.: Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005, 23:4634–4642. CrossRef
- Nachman JB, Sposto R, Herzog P, et al.: Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol 2002, 20:3765–3771. CrossRef
- Specht L, Gray RG, Clarke MJ, et al.: Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin’s Disease Collaborative Group. J Clin Oncol 1998, 16:830–843.
- Rehan FA, Brillant C, Schulz H, et al.: Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma [abstract 2320]. Blood (ASH Annual Meeting Abstracts) 2007, 110:2320.
- Kaplan H: The radical radiotherapy of Hodgkin’s disease. Radiology 1962, 78:553–561.
- Yahalom J: Changing role and decreasing size: current trends in radiotherapy for Hodgkin’s disease. Curr Oncol Rep 2002, 4:415–423. CrossRef
- Yahalom J: Favorable early-stage Hodgkin lymphoma. J Natl Compr Canc Netw 2006, 4:233–240.
- Hodgson DC, Koh ES, Tran TH, et al.: Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 2007, 110:2576–2586. CrossRef
- Goodman KA, Toner S, Hunt M, et al.: Intensity modulated radiation therapy in the treatment of lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 2005, 62:198–206. CrossRef
- Girinsky T, Pichenot C, Beaudre A, et al.: Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin’s disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 2006, 64:218–226.
- Travis LB, Gospodarowicz M, Curtis RE, et al.: Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 2002, 94:182–192.
- Travis LB, Hill DA, Dores GM, et al.: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin’s disease. JAMA 2003, 290:465–475. CrossRef
- Koontz B, Kirkpatrick J, Clough R, et al.: Combined modality therapy versus radiotherapy alone for treatment of early stage Hodgkin disease: Cure versus complications. J Clin Oncol 2006, 24:605–611. CrossRef
- Salloum E, Doria R, Schubert W, et al.: Second solid tumors in patients with Hodgkin’s disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 1996, 14:2435–2443.
- Bonadonna G, Bonfante V, Viviani S, et al.: ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 2004, 22:2835–2841. CrossRef
- Girinsky T, van der Maazen R, Specht L, et al.: Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006, 79:270–277. CrossRef
- Campbell BA, Voss N, Pickles T, et al.: Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol 2008, 26:5170–5174. CrossRef
- Hoppe RT, Advani RH, Ambinder RF, et al.: Hodgkin disease/lymphoma. J Natl Compr Canc Netw 2008, 6:594–622.
- Schlembach PJ, Wilder RB, Jones D, et al.: Radiotherapy alone for lymphocyte-predominant Hodgkin’s disease. Cancer J 2002, 8:377–383. CrossRef
- Prosnitz LR, Wu JJ, Yahalom J: The case for adjuvant radiation therapy in advanced Hodgkin’s disease. Cancer Invest 1996, 14:361–370. CrossRef
- Yahalom J, Ryu J, Straus DJ, et al.: Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin’s disease treated with alternating chemotherapy combinations. J Clin Oncol 1991, 9:2193–2201.
- Brizel DM, Winer EP, Prosnitz LR, et al.: Improved survival in advanced Hodgkin’s disease with the use of combined modality therapy. Int J Radiat Oncol Biol Phys 1990, 19:535–542.
- Fabian C, Mansfield C, Dahlberg S, et al.: Low-dose involved field radiation after chemotherapy in advanced Hodgkin’s disease. Ann Intern Med 1994, 120:903–912.
- Loeffler M, Brosteanu O, Hasenclever D, et al.: Metaanalysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International Database on Hodgkin’s Disease Overview Study Group. J Clin Oncol 1998, 16:818–829.
- Aleman BM, Raemaekers JM, Tirelli U, et al.: Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 2003, 348:2396–2406. CrossRef
- Duggan DB, Petroni GR, Johnson JL, et al.: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 2003, 21:607–614. CrossRef
- Horning SJ, Hoppe RT, Breslin S, et al.: Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 2002, 20:630–637. CrossRef
- Chisesi T, Federico M, Levis A, et al.: ABVD versus Stanford V versus MEC in unfavourable Hodgkin’s lymphoma: results of a randomised trial. Ann Oncol 2002, 13(Suppl 1):102–106.
- Poen JC, Hoppe RT, Horning SJ: High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin’s disease: the impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys 1996, 36:3–12. CrossRef
- Yahalom J, Gulati SC, Toia M, et al.: Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin’s disease. J Clin Oncol 1993, 11:1062–1070.
- Moskowitz CH, Nimer SD, Zelenetz AD, et al.: A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001, 97:616–623. CrossRef
- Moskowitz CH, Kewalramani T, Nimer SD, et al.: Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol 2004, 124:645–652. CrossRef
- Yahalom J: Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: a randomized study caveat. Leuk Lymphoma 2007, 48:1667–1669. CrossRef
- Does radiotherapy still have a place in Hodgkin lymphoma?
Current Hematologic Malignancy Reports
Volume 4, Issue 3 , pp 117-124
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Joachim Yahalom (1)
- Author Affiliations
- 1. Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10021, USA